

ASX RELEASE

28 September 2021

Amplia Presentation for Proactive Investors Lifesciences Webinar

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to provide the presentation that will be delivered at the Proactive Investors Lifesciences Webinar today, Tuesday 28 September 2021, at 12:00 pm AEST.

To join the webinar, please register at: <https://event.webinarjam.com/register/91/ggy97hzy>

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.

- End -

For Further Information

Dr. John Lambert
CEO and Managing Director
john@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Amplia Therapeutics (ASX:ATX)

September 2021

Amplia Therapeutics Limited



Disclaimer



The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Amplia Therapeutics Limited (“Amplia”) in any jurisdiction. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.

This presentation contains forward-looking statements which can be identified by the use of words such as “may”, “should”, “will”, “expect”, “anticipate”, “believe”, “estimate”, “intend”, “scheduled” or “continue” or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks, uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to Amplia, and its officers, employees, agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements.

There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. The data and results pertaining to clinical subjects used in this presentation are illustrative of medical conditions and outcomes associated with potential applications of Amplia’s acquired product pipeline. Actual results from clinical trials may vary from those shown.

Amplia Therapeutics is
developing new treatments
for cancer and fibrosis



Six Reasons to Invest in Amplia



Market cap. with headroom for growth



Forthcoming milestones

Highly experienced team




Diversified product pipeline

Best in class clinical-stage asset



Addressing seriously unmet medical needs

A pipeline built for growth



Unmet needs: Amplia's current focus



Pancreatic Cancer

- 60,000 new diagnoses from pancreatic cancer in the US each year
- Difficult-to-treat cancer that is often surrounded by a protective, fibrotic stromal layer
- Less than 20% patients eligible for surgery – chemo main treatment
- Few new therapies recently approved

AMP945 was awarded Orphan Drug Designation by the US FDA for use in treating Pancreatic Cancer in March 2020

Idiopathic Pulmonary Fibrosis (IPF)

- Affects ~3M people worldwide
- Devastating, progressive disease caused by the build up of fibrotic tissue in the lungs
- Approved drugs slow progression but are unable to stop the disease
- With treatment, median survival time is 3-5 years

AMP945 was awarded Orphan Drug Designation by the US FDA for use in treating Idiopathic Lung Fibrosis in May 2020

Why target pancreatic cancer and pulmonary fibrosis?



Pancreatic Cancer	Pulmonary Fibrosis
Preclinical data provides rationale for clinical study in this disease	
AMP945 enhances the efficacy in animal models	AMP945 effective in mouse model of IPF
Gateway indication to other fibrotic cancers/fibrotic diseases	
Ovarian cancer; Breast cancer; Hepatocellular carcinoma; Melanoma; Gastric cancer; Lung cancer	Liver fibrosis (NASH); Renal fibrosis; Wound healing
Unmet need, market size and partnering landscape	
Even incremental improvements will be widely accepted	Limited treatment options available
2021 Total Addressable Market (TAM) \$2B, forecast to grow to \$5.4B by 2029*	2021 TAM \$2.2B, forecast to grow to \$4.6B by 2027**
Kinase inhibitors expected to play an increasing role in treatment	Vibrant partnering landscape for fibrosis drugs


* GlobalData, *Pancreatic Cancer –Opportunity Analysis and Forecasts to 2029* (2020)

** ResearchAndMarkets, *Idiopathic Pulmonary Fibrosis - Global Market Trajectory & Analytics*, 2021

Recent deals for anti-fibrotic and pancreatic cancer drugs



Total disclosed upfront and milestones payments; excludes potential royalty payments



Successful Phase 1 clinical trial




- AMP945 was safe and well-tolerated at all doses tested
 - 56 participants: single and multiple doses
 - No Serious Adverse Events
 - Oral dosing
 - Once-a-day
 - No food effect
- Supports advancing AMP945 into Phase 2 clinical trials
 - Planning for Phase 2 trial in pancreatic cancer and pulmonary fibrosis underway
 - On track to initiate first Phase 2 clinical trial in Q1 2022



Planned clinical trial in pancreatic cancer



- The trial will test current chemotherapy* + AMP945
- Pancreatic cancer patients with Stage 3 or 4 disease
 - Inoperable or metastatic disease
- Approx. 60 first-line cancer patients
- Trial will assess
 - Preliminary efficacy of AMP945
 - Clinical endpoints, disease biomarkers
 - Safety and tolerability of AMP945



* Gemcitabine + nab-paclitaxel

Benefits of developing AMP945 as first-line therapy



Largest patient population: >70% newly diagnosed patients

- Largest addressable market opportunity
- Aids recruitment for clinical trials

Patients better able to respond

- treatment naïve
- better overall health

Minimal impact on current clinical practice


- integrates with established treatment
- will help acceptance and adoption

“With the exception of two targeted agents, which exhibited minimal or no overall survival benefit (erlotinib and olaparib), standard treatments are limited to conventional chemotherapies.”

“There have been no paradigm-shifting advances beyond combination chemotherapy in the pancreatic cancer field over the past two decades. This contrasts with many other common cancers, which have benefited from impactful targeted therapies.”

A comprehensive analysis of clinical trials in pancreatic cancer; what is coming down the pike? *Oncotarget* 2020, 11:3489-3501

Amplia's clinical trial schedule




HREC: Human Research Ethics Committee
 IND: Investigational New Drug

Amplia summary



- Amplia Therapeutics is an exciting company with a diversified product pipeline and high quality prospects in clinical development
 - Multiple value inflexions expected in the next 2-3 years
- AMP945 has completed a Phase 1 trial and is now poised for development in two therapeutic areas
 - Phase 2 trial in **pancreatic cancer** expected to commence recruitment in Q1 2022
 - Phase 2 trial in **pulmonary fibrosis** expected to commence recruitment in Q3 2022



THANK YOU



ampliatx.com